Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

The conversation is about the use and application of CB-03-01-2 (Breezula) for hair loss, including questions about its form, how to apply it, and the duration 10g would last. Specific treatments discussed are Minoxidil, finasteride, and RU58841.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

The user applies 2ml of a lotion containing 5% minoxidil, 0.3% finasteride, hydrocortisone butyrate, and cetirizine before bed, but it leaves a residue on the scalp. Another user suggests reducing the amount to 1ml, as 2ml results in a high finasteride dosage.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

The user is considering making a homemade topical finasteride solution using an ethanol-based carrier. They are inquiring if a solution containing partially denatured ethyl alcohol and benzalkonium chloride is suitable.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

Switching from minoxidil foam to topical solution and considering adding caffeine, melatonin, or cetirizine. Currently using 2.5mg oral minoxidil and 1mg oral finasteride, planning to ask for 0.5mg oral dutasteride and 5mg oral minoxidil.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

A user plans to create a custom topical solution by adding finasteride, caffeine, cetirizine, and melatonin to a minoxidil bottle, questioning the stability and effectiveness of this mix. Concerns include potential crystallization and solution muddiness with added ingredients.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.